The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

Shares of PVH Corp. fell after hours on Wednesday after the Calvin Klein and Tommy Hilfiger parent cut its full-year profit outlook, citing the impact of tariffs on shipments heading into the U.S.

Bankrupt genetic analysis company 23andMe will hold a second auction for its cache of DNA data with an opening bid of $305 ...

Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its ...

The judge overseeing the bankruptcy of 23andMe questioned the limits proposed for a second auction that is designed to push ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Apple Inc.'s stock has struggled to find positive momentum this year, and analysts at Needham & Company don't see major catalysts ahead that can help put shares on a better course.